Company profile
KScan phosphoproteomic diagnostic platform developed by Kinomica
Kinomica developed KScan, a phosphoproteomic diagnostic platform to help clinicians prescribe the right drug.
Financial period: 1 Jul 2024 to 30 Jun 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
RESOLUTIONS | Transaction WUVZV1lEV1lhZGlxemtjeA | Paper/PDF filed
Published 17 Apr 2026 01:13
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQ0MDIyMTk2M2FkaXF6a2N4 | Paper/PDF filed
Published 22 Oct 2024 06:36
SH01 | Transaction MzQzNDYwOTIwNWFkaXF6a2N4
Published 05 Sep 2024 08:29
PSC08 | Transaction MzQzNDYwOTE0NGFkaXF6a2N4
Published 05 Sep 2024 08:29
MA | Transaction MzQzMzY2OTA3OGFkaXF6a2N4 | Paper/PDF filed
Published 03 Sep 2024 07:01
RESOLUTIONS | Transaction WUQ5Wk5OQTlhZGlxemtjeA | Paper/PDF filed
Published 28 Aug 2024 07:14
PSC07 | Transaction MzQzMjUxOTMxMmFkaXF6a2N4
Published 16 Aug 2024 16:29
PSC07 | Transaction MzQzMjUxOTI4OGFkaXF6a2N4
Published 16 Aug 2024 16:28
SH01 | Transaction MzQzMjUxOTA4NGFkaXF6a2N4
Published 16 Aug 2024 16:25
Company registered at Companies House
Kinomica develops precision medicine technology for a range of applications.
Kinomica seeks to develop and commercialise companion diagnostic tests based on technology developed at QMUL.
In the last 18 months Kinomica received £970,000 of seed funding and £3.9M Series A funding. This is allowing the company to commercialise outputs from this research.
1 Jan 2023 to 30 Jun 2024
Decades of intensive research has produced a wealth of anticancer treatments. A problem for the success of these therapies is that not all patients will respond to treatments in the same way, so some may respond well to a treatment while others respond poorly to that same treatment. It is difficult therefore to know, or predict, which patients will be res...
1 Apr 2022 to 31 Mar 2025
Primary liver cancer is the fourth most prevalent cancer globally and the third highest cause of cancer deaths. Rising incidence coupled with an appalling 5-year survival rate of less than 15% is forecast to result in up to 1 million deaths in 2030\. Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancer cases, with around 5,900 new cases...
1 Jul 2019 to 31 Mar 2022
"Acute myeloid leukaemia (AML) is an aggressive form of blood cancer, where only about 20% of patients are expected to survive for 5 or more years after diagnosis. A new drug called midostaurin can triple survival times for some patients and is now available on the NHS. However, only a subgroup of AML patients (~30%) are eligible to receive this treatment...
